Objective To investigate the role of serum N-glycan markers for monitoring liver fibrosis regression in chronic hepatitis B patients receiving antiviral therapy.Methods A total of 128 chronic hepatitis B patients recruited from 33 hospitals nationwide during 2013-2020 had received antiviral therapy of 78 weeks and been followed-up for every 3-month.All patients had undergone liver biopsy at baseline and 78-week,and the liver fi-brosis stages were assessed using the Ishak scoring system.Serum N-glycan profiles were analyzed using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis(DSA-FACE).Serum N-glycan RF-R,SVM-R and LR-R models were constructed by random forest(RF),support vector machine(SVM)and logis-tic regression(LR)analysis,to predict the regression of liver fibrosis in patients receiving antiviral therapy.Results After antiviral therapy of 78 weeks,89(69.53％)chronic hepatitis B patients achieved liver fibrosis re-gression(Ishak score decreased by at least 1 point).The changes of serum N-glycan peaks 1～7 were associated with liver fibrosis regression.In the training cohort,the diagnostic area under receiver operating characteristic curve(AUROC)of the serum N-glycan RF-R,SVM-R and LR-R models were 0.97,0.97 and 0.69,respec-tively,and the coincidence rate with liver biopsy were 89.77％,84.09％and 69.32％,respectively.Similar re-sults had been observed in the validation group.Conclusions Serum N-glycan biomarkers may predict liver fi-brosis regression for chronic hepatitis B patients receiving antiviral therapy.
维普
万方数据